Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$36.06
+2.0%
$31.92
$23.42
$62.58
$2.09B0.73652,247 shs258,713 shs
Arvinas, Inc. stock logo
ARVN
Arvinas
$7.89
-0.1%
$7.30
$5.90
$34.11
$580.28M2.171.46 million shs826,658 shs
FibroGen, Inc stock logo
FGEN
FibroGen
$5.69
+8.4%
$7.16
$4.50
$38.25
$22.67M0.7476,019 shs33,072 shs
Hypermarcas stock logo
HYPMY
Hypermarcas
$5.03
+0.1%
$4.44
$2.64
$5.92
$3.18B0.81187,081 shs2.73 million shs
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$2.23
-2.6%
$1.65
$0.60
$3.08
$175.57M1.4390,987 shs358,562 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
0.00%+7.72%+5.95%+39.97%-14.20%
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%+4.66%+13.54%+20.29%-66.98%
FibroGen, Inc stock logo
FGEN
FibroGen
0.00%+9.00%-25.40%-18.71%-67.06%
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00%+3.62%+10.46%+39.99%-1.80%
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
0.00%-13.23%+24.58%+227.94%+48.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.1244 of 5 stars
3.41.00.04.32.00.81.9
Arvinas, Inc. stock logo
ARVN
Arvinas
3.1128 of 5 stars
4.32.00.00.00.02.51.3
FibroGen, Inc stock logo
FGEN
FibroGen
4.7169 of 5 stars
3.33.00.04.74.43.30.6
Hypermarcas stock logo
HYPMY
Hypermarcas
N/AN/AN/AN/AN/AN/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.1179 of 5 stars
3.73.00.00.02.91.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
2.71
Moderate Buy$58.6062.53% Upside
Arvinas, Inc. stock logo
ARVN
Arvinas
2.55
Moderate Buy$20.29157.12% Upside
FibroGen, Inc stock logo
FGEN
FibroGen
2.50
Moderate Buy$250.004,293.67% Upside
Hypermarcas stock logo
HYPMY
Hypermarcas
0.00
N/AN/AN/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
3.33
Buy$6.00169.06% Upside

Current Analyst Ratings Breakdown

Latest ARVN, IMAB, HYPMY, AGIO, and FGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.00 ➝ $5.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$24.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$10.00 ➝ $9.00
6/1/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/15/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$74.00 ➝ $21.00
5/13/2025
FibroGen, Inc stock logo
FGEN
FibroGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$250.00 ➝ $250.00
5/9/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$12.00 ➝ $11.00
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.50
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $10.00
5/5/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$21.00 ➝ $11.00
5/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$16.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$36.50M57.21N/AN/A$27.02 per share1.33
Arvinas, Inc. stock logo
ARVN
Arvinas
$263.40M2.19N/AN/A$8.17 per share0.97
FibroGen, Inc stock logo
FGEN
FibroGen
$29.62M0.78N/AN/A($50.89) per share-0.11
Hypermarcas stock logo
HYPMY
Hypermarcas
$1.38B2.31$0.47 per share10.64$3.54 per share1.42
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
$3.89M46.81N/AN/A$2.47 per share0.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
$673.72M$11.243.21N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)
Arvinas, Inc. stock logo
ARVN
Arvinas
-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)
FibroGen, Inc stock logo
FGEN
FibroGen
-$47.58M-$2.50N/AN/AN/A-9.73%N/A-24.77%8/5/2025 (Estimated)
Hypermarcas stock logo
HYPMY
Hypermarcas
$248.62M$0.2420.94N/A12.51%6.95%3.34%7/23/2025 (Estimated)
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
-$22.23MN/A0.00N/AN/AN/A-19.81%-18.63%8/27/2025 (Estimated)

Latest ARVN, IMAB, HYPMY, AGIO, and FGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.87N/AN/AN/A$34.42 millionN/A
5/12/2025Q1 2025
FibroGen, Inc stock logo
FGEN
FibroGen
$0.75-$4.00-$4.75$0.05$2.00 million$2.70 million
5/1/2025Q1 2025
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million
5/1/2025Q1 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.93$1.14+$2.07$1.14$41.87 millionN/A
4/23/2025Q1 2025
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A-$0.04N/A-$0.04N/A$184.34 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/AN/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
FibroGen, Inc stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.142.79%N/A58.33%N/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/AN/AN/AN/AN/A

Latest ARVN, IMAB, HYPMY, AGIO, and FGEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Hypermarcas stock logo
HYPMY
Hypermarcas
$0.03452.81%6/30/20257/1/20251/8/2027
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
18.50
17.93
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.58
4.58
FibroGen, Inc stock logo
FGEN
FibroGen
N/A
2.02
1.98
Hypermarcas stock logo
HYPMY
Hypermarcas
0.63
1.26
0.80
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
N/A
22.35
22.35

Institutional Ownership

CompanyInstitutional Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
N/A
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
FibroGen, Inc stock logo
FGEN
FibroGen
72.71%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38.38%

Insider Ownership

CompanyInsider Ownership
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
4.30%
Arvinas, Inc. stock logo
ARVN
Arvinas
4.73%
FibroGen, Inc stock logo
FGEN
FibroGen
3.07%
Hypermarcas stock logo
HYPMY
Hypermarcas
N/A
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
22.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agios Pharmaceuticals, Inc. stock logo
AGIO
Agios Pharmaceuticals
39057.92 million55.43 millionOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
42072.99 million69.54 millionOptionable
FibroGen, Inc stock logo
FGEN
FibroGen
5704.04 million3.92 millionOptionable
Hypermarcas stock logo
HYPMY
Hypermarcas
10,481633.42 millionN/ANot Optionable
I-Mab Sponsored ADR stock logo
IMAB
I-Mab
38081.66 million63.61 millionOptionable

Recent News About These Companies

I-Mab (NASDAQ:IMAB) Price Target Raised to $5.00
I-Mab regains compliance with Nasdaq’s listing rule

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agios Pharmaceuticals stock logo

Agios Pharmaceuticals NASDAQ:AGIO

$36.06 +0.71 (+1.99%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$36.06 0.00 (0.00%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Arvinas stock logo

Arvinas NASDAQ:ARVN

$7.89 -0.01 (-0.11%)
Closing price 07/3/2025 02:37 PM Eastern
Extended Trading
$7.96 +0.07 (+0.87%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

FibroGen stock logo

FibroGen NASDAQ:FGEN

$5.69 +0.44 (+8.38%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$5.61 -0.08 (-1.41%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Hypermarcas stock logo

Hypermarcas OTCMKTS:HYPMY

$5.03 +0.01 (+0.12%)
As of 07/3/2025 12:21 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

I-Mab stock logo

I-Mab NASDAQ:IMAB

$2.23 -0.06 (-2.62%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$2.23 0.00 (0.00%)
As of 07/3/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.